Objective. Central sensitization (CS) with low peripheral pain thresholds (PPTs) is a common finding among patients with chronic pain after whiplash (CPWI). While it has been proposed that myofascial myofascial trigger points (MTrPs) may act as modulators of central sensitization, previously reported findings are conflicting and inconclusive. The present study was designed to investigate immediate responsiveness of CS to alterations in nociceptive input.
Introduction
Central sensitization (CS) is a condition in which peripheral thresholds for pain from pressure, temperature, electrical, and other stimuli are abnormally low [1, 2] . CS-related hyperalgesia features prominently in chronic pain syndromes, including chronic whiplash (CPWI) [3] [4] [5] , and has been described as "a concept of great importance in clinical medicine" [6] .
So-called myofascial trigger points (MTrPs), defined as "a discrete, hyperirritable nodule in a taut band of skeletal muscle which is palpable and tender during physical examination" [7] are common in association with both CS and CPWI. The relationship between CS and MTrPs is intimate, and it has been argued both that MTrPs are expressions of CS and that CS may be a promotor of MTrPs [8] , with a possibility of the two being linked in a potentially spiraling positive feedback system. It has been proposed that myofascial trigger points (MTrPs), a common finding in CPWI [9, 10] , may function as a peripheral mediator of CS [11] . Curatolo and colleagues investigated the effect of local anesthetic injection in painful muscles in 14 patients with CPWI and 14 controls and reported that the injections did not alter the lowered pain thresholds in the neck and lower limbs in the CPWI group [12] . More recently, we presented the results from an open study where local anesthetic injections were given to carefully selected MTrPs/tender points in 17 patients with CPWI [13] . Pre-and postinjection cervical range of motion, pressure pain thresholds over the infraspinatus, wrist extensor and anterior tibial muscles, light sensitivity (photophobia), and general pain level were measured. In contrast with the findings by Curatolo et al., we found that subjects experienced a nearly instantaneous (within one minute) increase in pressure pain thresholds and cervical range of motion, and decreased general pain and light sensitivity. Pre-and postinjection pressure pain thresholds were also measured in a control group of 10 subjects who received a local anesthetic injection to the thigh, with no changes in any of the variables.
Valid criticism of our prior study includes that the lack of blinding and randomization weakens the conclusion that ablating MTrPs may hypothetically serve to attenuate signs and symptoms of CS-related hyperalgesia. The aim of the present investigation was to address those weaknesses and to further study a presumed interaction between CS and MTrPs in chronic whiplash according to a rigorous, randomized, double-blind crossover protocol.
Methods
Thirty-five consecutive patients who sought medical care for chronic (>12 months) pain in the neck and shoulders after a whiplash trauma, and who had history and clinical signs consistent with CS [14] , were recruited to the study. Concurrent shoulder, head, thoracic, or low back pain was acceptable for participation, whereas patients were excluded from the study if they presented with signs or symptoms of radiculopathy or myelopathy, radiographic evidence of significant spine pathology such as tumor or recent fracture, or any suspicion of systemic illness as the cause of chronic pain. Thirty-one subjects met the inclusion criteria (Table 1 ) and were enrolled. A summary of the study protocol is provided in Figure 1 .
Informed consent was obtained from all participants, and institutional review board oversight and approval was provided by the Spinal Injury Foundation in Westminster, Colorado.
The study was conducted in three phases, as follows:
Phase I

Mapping of Tender Points
Prior to randomization, one distinct MTrP [7] or focal area of significant pain ("tender point") was identified in the horizontal segment of the trapezius muscle, cranial to the spine of the scapula and on the side that was indicated by the participant as most painful. The location of the MTrP was indicated with permanent marker on the overlying skin.
Data Collection
All measurements and collections of data were performed by one investigator (MDF) in a standardized manner. Measurements for each of the following variables were obtained three times for averages:
• Unilateral pressure pain thresholds (PPT): Algometer (Wagner Instruments, Greenwich, CT, USA) over ipsilateral muscles in the shoulder (trapezius/infraspinatus, caudal to the spine of the scapula), forearm (brachioradialis), Figure 1 Summary representation of the study design. and lower leg (tibialis anterior). A tape measure was used to ascertain standardized positioning of the points of measurement, with minimal variation between participants. At each site, pressure against the instrument was increased steadily until the threshold for pain was reached as signaled verbally by the participant.
• Grip strength: Martin Vigorimeter.
• Jaw opening (maximum voluntary inter-incisory distance); calipers.
• Overall pain at rest: linear visual analogue scale (VAS) graded from 0 (no pain) to 10 (worst pain ever experienced).
Randomization
At completion of phase I and collection of baseline data, participants were randomly assigned to group A (study; N ¼ 15) or group B (control þ crossover; N ¼ 16) based on the sum of individual dates of birth (odd or even). All participants and the investigator performing measurements and data collection were blinded for the randomization.
Phase II
Blinded Interventions
Group A: Using a 25 g needle, a subfascial injection (TPI) of 2 mL Bupivacaine 0.25 mg/mL was administered according to the skin mark that had been placed prior to randomization. This and all subsequent injections were provided by one investigator (NAN).
Group B: A sham injection of 0.5 mL local anesthetic solution (Bupivacaine 0.25 mg/mL) was given intradermally at the skin mark. The technique was designed to produce injection pain similar to that experienced by participants in group A, with minimal risk of any local anesthetic reaching the underlying myofascial tissues.
Data Collection
Repeat measurements for PPT, Grip, Jaw opening and Pain, were made as described under Phase I, beginning within two minutes, and in all cases completed within five minutes of the injection.
Phase III
Crossover
Group B: Following sham injection and measurements and a washout period of no fewer than 30 minutes, participants were informed of the result of randomization. A TPI was thereafter performed as described in the Phase II section.
Data Collection
Statistical Analysis
Student's unpaired t test was used to evaluate for differences in mouth opening, grip strength, and VAS for data collected before and after injection for both groups, and before and after crossover (group B).
Paired one-way analysis of variance (ANOVA) was used to evaluate PPT values in three muscles (trapezius/infaspinatus, brachioradialis, and tibialis anterior) before and after TPI or sham injection (group A and B), and after sham injection or crossover (group B). ANOVA of independent samples was used to test for differences between baseline PPT in both groups, and then again to compare PPT after TPI in group A with PPT in group B after crossover.
Statistical significance was set at a P value of less than 0.05. All statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Results
Phase I
No statistically significant differences were found between group A and group B for age, gender, time from injury, or baseline pain at rest (Table 2) .
Phase II
• PPT: Significantly higher PPT values were found in group A but not in group B following TPI or sham injection, respectively (Table 3 ).
• Grip: There were no significant changes in grip strength in group A or group B after TPI or sham injection, respectively (Table 4 ).
• Jaw opening: Maximum voluntary jaw opening was significantly increased in group A but not in group B after TPI or sham injection, respectively (Table 4 ).
• Pain: VAS scores for overall pain after TPI and placebo were significantly lower in both groups (Table 4) . Phase III
Crossover
Significant improvement was documented for all six variables after crossover into the treatment arm for group B (Table 5 ).At the conclusion of phase III, no significant differences remained between group A and group B, with the exception of grip strength (Table 6 ).
Discussion
PPT is an adequate outcome parameter in studies relating to CS as "the net effect of central sensitization is to recruit previously subthreshold synaptic inputs to nociceptive neurons" [15] . In this investigation, peripheral pressure pain thresholds were found to rise rapidly and significantly after anesthetization of a single pain generator in the upper trapezius or its overlying fascia. The benefit of a randomized and placebo-controlled design is apparent from the results seen in phase II as overall pain levels were rated lower in both group A and group B, while the objective parameters improved only in group A.
Emotional factors, including expectation, influence the perception of pain. Similarly, any manipulation of a MTrP, or injection, for example, with normal saline or local anesthetic, is likely to trigger a response of increased or decreased pain. Therefore, two techniques that differed only with regard to their respective depth of injection (intradermal vs subfascial) were used in this study, defining "intradermal" as "placebo." As participants in group B described injections as no less painful or uncomfortable than participants in group A, we consider phase II free from expectation bias.
The crossover design adopted for phase III of the study was specifically implemented to assess the effect of expectation. As there were no statistically significant differences between groups after crossover and as objective parameters changed only when local anesthetic was delivered subfascially as opposed to intradermally, we conclude that criteria for placebo or sham injection were effectively met.
The rapid reversal of CS, as represented in this study by higher peripheral pain thresholds after TPI, is consistent with the results from our prior open study but stands in contrast with findings by Curatolo et al., who reported that "anesthesia of the painful and tender points affected neither intensity of neck pain nor pain thresholds" [12] . Reasons for the stark differences in outcome are not entirely clear; however, we followed a standardized protocol in identifying a single dominant MTrPt for injection in the horizontal trapezius muscle, whereas Curatolo et al. described a possibly less specific routine. We do not exclude that the differing results may be a function of expectation bias or variations in injection technique, data gathering, etc.
Complaints of jaw pain and other symptoms that may be consistent with temporomandibular joint dysfunction (TMD) are frequent among patients with CPWI [16] , but surgical or conservative treatment strategies for temporomandibular joint (TMJ) dysfunction have not provided encouraging results [17] . One theory related to the genesis of TMD in CPWI correlates dysfunction of the jaw muscles with that of muscles in the neck [18] , and whiplash trauma leading to chronic neck pain has been proposed as root cause of TMJ dysfunction in some cases [19] . That theory may be further supported by the present findings of lessened jaw pain and improved TMJ function after a single TPI in the trapezius. 
Central Sensitization Is Modulated Following Trigger Point Anesthetization
Observations of rapidly adjusting peripheral pain thresholds after anesthetization of a single MTrP do not contradict any existing evidence of neuronal plasticity as a reason for widespread pain, for example, in chronic whiplash, and surgical removal of myofascial pain generators may in that context deserve consideration as an alternative to pharmacological treatment for CS [20] . We have previously published encouraging results from surgical resection of painful tender points in selected patients with CPWI [21] [22] [23] . The current findings offer an explanatory model for such results; in at least some patients with CPWI-associated CS, peripheral tender points or MTrPs serve to modulate lowered bodily pain thresholds. A clinical investigation is ongoing to further test the hypothesis. 
